The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Open accessAbstract
Objective To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. Methods Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry. Results Twelve patients were randomized to receive golodirsen (n = 8) or placebo (n = 4) in part 1. All from part 1 plus 13 additional patients received 30 mg/kg golodirsen in part 2. Safety findings were consistent with those previously observed in pediatric patients with DMD. Most of the study drug was excreted within 4 hours following administration. A significant increase in exon 53 skipping was associated with ∼16-fold increase over baseline in dystrophin protein expression at week 48, with a mean percent normal dystrophin protein standard of 1.019% (range, 0.09%–4.30%). Sarcolemmal localization of dystrophin was demonstrated by significantly increased dystrophin-positive fibers (week 48, p < 0.001) and a positive correlation (Spearman r = 0.663; p < 0.001) with dystrophin protein change from baseline, measured by Western blot and immunohistochemistry. Conclusion Golodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed increased exon 53 skipping, dystrophin production, and correct dystrophin sarcolemmal localization. Clinicaltrials.gov identifier NCT02310906. Classification of evidence This study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Prevalence of Muscular Dystrophies: A Systematic Literature Review
Theadom, A., Rodrigues, M., Roxburgh, R., Balalla, S., Higgins, C., Bhattacharjee, R., Jones, K., Krishnamurthi, R., & Feigin, V. (2014) · Neuroepidemiology · doi:10.1159/000369343 · Cited by 2,046
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Self-citationEteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Self-citation
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
Self-citationAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Metadata
- Authors
- Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., Straub, V., Guglieri, M., Mercuri, E., Servais, L., Muntoni, F., & on behalf of the SKIP-NMD Study Group
- Venue
- Neurology
- Published
- 2020-05-26
- Volume
- 94
- Issue
- 21
- Pages
- e2270-e2282
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3010225431
- Cited by
- 332
- References
- 32
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1212/wnl.0000000000009233
- The paper
- Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., Straub, V., Guglieri, M., Mercuri, E., Servais, L., Muntoni, F., & on behalf of the SKIP-NMD Study Group. (2020). Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. https://doi.org/10.1212/wnl.0000000000009233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.